David J Waxman

List of Publications by Year
in descending order

263 papers	22,647 citations	13099 68 h-index	9589 142 g-index
287 all docs	287 docs citations	287 times ranked	15564 citing authors

#	Article	IF	Citations
1	P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics and Genomics, 1996, 6, 1-42.	5.7	2,629
2	The P450 Superfamily: Update on New Sequences, Gene Mapping, Accession Numbers, Early Trivial Names of Enzymes, and Nomenclature. DNA and Cell Biology, 1993, 12, 1-51.	1.9	1,596
3	The P450 Superfamily: Update on New Sequences, Gene Mapping, and Recommended Nomenclature. DNA and Cell Biology, 1991, 10, 1-14.	1.9	1,086
4	P450 Gene Induction by Structurally Diverse Xenochemicals: Central Role of Nuclear Receptors CAR, PXR, and PPAR. Archives of Biochemistry and Biophysics, 1999, 369, 11-23.	3.0	695
5	Sex Differences in the Expression of Hepatic Drug Metabolizing Enzymes. Molecular Pharmacology, 2009, 76, 215-228.	2.3	601
6	Regulation of rat hepatic cytochrome P-450: age-dependent expression, hormonal imprinting, and xenobiotic inducibility of sex-specific isoenzymes. Biochemistry, 1985, 24, 4409-4417.	2.5	595
7	Interactions of hepatic cytochromes P-450 with steroid hormones. Biochemical Pharmacology, 1988, 37, 71-84.	4.4	450
8	Activation of PPARÂ and PPARÂ by Environmental Phthalate Monoesters. Toxicological Sciences, 2003, 74, 297-308.	3.1	440
9	Human liver microsomal steroid metabolism: Identification of the major microsomal steroid hormone 6Î²-hydroxylase cytochrome P-450 enzyme. Archives of Biochemistry and Biophysics, 1988, 263, 424-436.	3.0	412
10	Growth Hormone Regulation of Sex-Dependent Liver Gene Expression. Molecular Endocrinology, 2006, 20, 2613-2629.	3.7	391
11	MAnorm: a robust model for quantitative comparison of ChIP-Seq data sets. Genome Biology, 2012, 13, R16.	9.6	355
12	trans-Activation of PPARÎ± and PPARÎ³ by Structurally Diverse Environmental Chemicals. Toxicology and Applied Pharmacology, 1999, 161, 209-218.	2.8	350
13	SOCS/CIS Protein Inhibition of Growth Hormone-stimulated STAT5 Signaling by Multiple Mechanisms. Journal of Biological Chemistry, 1999, 274, 35553-35561.	3.4	317
14	Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Molecular Cancer Therapeutics, 2008, 7, 3670-3684.	4.1	311
15	Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s. Archives of Biochemistry and Biophysics, 1991, 290, 160-166.	3.0	297
16	Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy. Cancer Letters, 2018, 419, 210-221.	7.2	251
17	Markedly Enhanced Cytochrome P450 2E1 Induction and Lipid Peroxidation Is Associated with Severe Liver Injury in Fish Oilâ€"Ethanolâ€Fed Rats. Alcoholism: Clinical and Experimental Research, 1994, 18, 1280-1285.	2.4	250
18	Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide. Biochemical Pharmacology, 2000, 59, 961-972.	4.4	234

#	Article	IF	Citations
19	Arachidonic acid metabolism by human cytochrome P450s 2C8, 2C9, 2E1, and 1A2: Regioselective oxygenation and evidence for a role for CYP2C enzymes in arachidonic acid epoxygenation in human liver microsomes. Archives of Biochemistry and Biophysics, 1995, 320, 380-389.	3.0	222
20	Sex-Dependent Liver Gene Expression Is Extensive and Largely Dependent upon Signal Transducer and Activator of Transcription 5b (STAT5b): STAT5b-Dependent Activation of Male Genes and Repression of Female Genes Revealed by Microarray Analysis. Molecular Endocrinology, 2006, 20, 1333-1351.	3.7	220
21	Intermittent Plasma Growth Hormone Triggers Tyrosine Phosphorylation and Nuclear Translocation of a Liver-Expressed, Stat 5-related DNA Binding Protein.. Journal of Biological Chemistry, 1995, 270, 13262-13270.	3.4	216
22	Growth Hormone Activation of Stat 1, Stat 3, and Stat 5 in Rat Liver. Journal of Biological Chemistry, 1996, 271, 5929-5940.	3.4	206
23	Metronomic chemotherapy: An attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance. Cancer Letters, 2015, 358, 100-106.	7.2	194
24	Interaction of Growth Hormone-activated STATs with SH2-containing Phosphotyrosine Phosphatase SHP-1 and Nuclear JAK2 Tyrosine Kinase. Journal of Biological Chemistry, 1997, 272, 17694-17702.	3.4	187
25	STAT5b Is Required for GH-Induced Liver Igf-I Gene Expression. Endocrinology, 2001, 142, 3836-3841.	2.8	151
26	Distinctive Roles of STAT5a and STAT5b in Sexual Dimorphism of Hepatic P450 Gene Expression. Journal of Biological Chemistry, 1999, 274, 7421-7430.	3.4	149
27	Experimental Tumor Therapy in Mice Using the Cyclophosphamide-Activating Cytochrome P450 2B1 Gene. Human Gene Therapy, 1994, 5, 969-978.	2.7	144
28	Dynamic, Sex-Differential STAT5 and BCL6 Binding to Sex-Biased, Growth Hormone-Regulated Genes in Adult Mouse Liver. Molecular and Cellular Biology, 2012, 32, 880-896.	2.3	144
29	Transcriptional Profiling of Human Liver Identifies Sex-Biased Genes Associated with Polygenic Dyslipidemia and Coronary Artery Disease. PLoS ONE, 2011, 6, e23506.	2.5	143
30	trans-Activation of PPARÂ and Induction of PPARÂ Target Genes by Perfluorooctane-Based Chemicals. Toxicological Sciences, 2004, 80, 151-160.	3.1	141
31	Genome-Wide Analysis of Chromatin States Reveals Distinct Mechanisms of Sex-Dependent Gene Regulation in Male and Female Mouse Liver. Molecular and Cellular Biology, 2013, 33, 3594-3610.	2.3	140
32	Synthetic Drugs and Natural Products as Modulators of Constitutive Androstane Receptor (Car) and Pregnane X Receptor (PXR). Drug Metabolism Reviews, 2006, 38, 51-73.	3.6	138
33	Cytochrome P-450 isozyme 1 from phenobarbital-induced rat liver: purification, characterization, and interactions with metyrapone and cytochrome b5. Biochemistry, 1983, 22, 4846-4855.	2.5	137
34	Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359allele as low-Kmcatalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics and Genomics, 1997, 7, 211-221.	5.7	136
35	Sexually Dimorphic P450 Gene Expression in Liver-Specific Hepatocyte Nuclear Factor 4Î±-Deficient Mice. Molecular Endocrinology, 2004, 18, 1975-1987.	3.7	132
36	17Î²-Estradiol 2- and 4-Hydroxylation Catalyzed by Rat Hepatic Cytochrome P-450: Roles of Individual Forms, Inductive Effects, Developmental Patterns, and Alterations by Gonadectomy and Hormone Replacement*. Endocrinology, 1986, 118, 1952-1960.	2.8	129

#	Article	IF	Citations
37	Cyclophosphamide Induces Caspase 9-Dependent Apoptosis in 9L Tumor Cells. Molecular Pharmacology, 2001, 60, 1268-1279.	2.3	127
38	Sexual Dimorphism of Rat Liver Gene Expression: Regulatory Role of Growth Hormone Revealed by Deoxyribonucleic Acid Microarray Analysis. Molecular Endocrinology, 2004, 18, 747-760.	3.7	127
39	Regulation of Signal Transducer and Activator of Transcription (STAT) 5b Activation by the Temporal Pattern of Growth Hormone Stimulation. Molecular Endocrinology, 1997, 11, 400-414.	3.7	119
40	Cross-talk between Janus Kinase-Signal Transducer and Activator of Transcription (JAK-STAT) and Peroxisome Proliferator-activated Receptor-Î± (PPARÎ±) Signaling Pathways. Journal of Biological Chemistry, 1999, 274, 2672-2681.	3.4	118
41	Role of the Cytokine-inducible SH2 Protein CIS in Desensitization of STAT5b Signaling by Continuous Growth Hormone. Journal of Biological Chemistry, 2000, 275, 39487-39496.	3.4	108
42	Codependence of Growth Hormone-Responsive, Sexually Dimorphic Hepatic Gene Expression on Signal Transducer and Activator of Transcription 5b and Hepatic Nuclear Factor 4Î±. Molecular Endocrinology, 2006, 20, 647-660.	3.7	105
43	Plasma Growth Hormone Pulse Activation of Hepatic JAK-STAT5 Signaling: Developmental Regulation and Role in Male-Specific Liver Gene Expression. Endocrinology, 2000, 141, 3245-3255.	2.8	99
44	Unbiased, Genome-Wide In Vivo Mapping of Transcriptional Regulatory Elements Reveals Sex Differences in Chromatin Structure Associated with Sex-Specific Liver Gene Expression. Molecular and Cellular Biology, 2010, 30, 5531-5544.	2.3	98
45	Loss of Sexually Dimorphic Liver Gene Expression upon Hepatocyte-Specific Deletion of Stat5a-Stat5b Locus. Endocrinology, 2007, 148, 1977-1986.	2.8	97
46	Activation of the Anticancer Prodrugs Cyclophosphamide and Ifosfamide: Identification of Cytochrome P450 2B Enzymes and Site-Specific Mutants with Improved Enzyme Kinetics. Molecular Pharmacology, 2004, 65, 1278-1285.	2.3	96
47	STAT5b-deficient Mice Are Growth Hormone Pulse-resistant. Journal of Biological Chemistry, 1999, 274, 35331-35336.	3.4	95
48	Female-Predominant Rat Hepatic P-450 Forms j (IIE1) and 3 (IIA1) Are under Hormonal Regulatory Controls Distinct from Those of the Sex-Specific P-450 Forms*. Endocrinology, 1989, 124, 2954-2966.	2.8	92
49	Chiral sulfoxidations catalyzed by rat liver cytochromes P-450. Biochemistry, 1982, 21, 2499-2507.	2.5	89
50	Directed Evolution of Mammalian Cytochrome P450 2B1. Journal of Biological Chemistry, 2005, 280, 19569-19575.	3.4	89
51	Intrinsic Sex Differences in the Early Growth Hormone Responsiveness of Sex-Specific Genes in Mouse Liver. Molecular Endocrinology, 2010, 24, 667-678.	3.7	89
52	Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8⁺T-cell responses and immune memory. OncoImmunology, 2015, 4, e1005521.	4.6	88
53	Liver-Specific Hepatocyte Nuclear Factor-4Î± Deficiency: Greater Impact on Gene Expression in Male than in Female Mouse Liver. Molecular Endocrinology, 2008, 22, 1274-1286.	3.7	87
54	Pituitary Regulation of the Male-Specific Steroid 6Î²-Hydroxylase P-450 2a (gene product IIIA2) in Adult Rat Liver. Suppressive Influence of Growth Hormone and Thyroxine Acting at a Pretranslational Level. Molecular Endocrinology, 1990, 4, 447-454.	3.7	86

#	Article	IF	Citations
55	Feminization of Male Mouse Liver by Persistent Growth Hormone Stimulation: Activation of Sex-Biased Transcriptional Networks and Dynamic Changes in Chromatin States. Molecular and Cellular Biology, 2017, 37, .	2.3	86
56	STAT5 Signaling in Sexually Dimorphic Gene Expression and Growth Patterns. American Journal of Human Genetics, 1999, 65, 959-965.	6.2	85
57	Growth Hormone Determines Sexual Dimorphism of Hepatic Cytochrome P450 3A4 Expression in Transgenic Mice. Journal of Pharmacology and Experimental Therapeutics, 2006, 316, 1328-1334.	2.5	84
58	Harnessing apoptosis for improved anticancer gene therapy. Cancer Research, 2003, 63, 8563-72.	0.9	82
59	Regulation of liver-specific steroid metabolizing cytochromes P450: Cholesterol 7Î±-hydroxylase, bile acid 6Î²-hydroxylase, and growth hormone-responsive steroid hormone hydroxylases. Journal of Steroid Biochemistry and Molecular Biology, 1992, 43, 1055-1072.	2.5	80
60	Impact of CUX2 on the Female Mouse Liver Transcriptome: Activation of Female-Biased Genes and Repression of Male-Biased Genes. Molecular and Cellular Biology, 2012, 32, 4611-4627.	2.3	80
61	Growth Hormone, but Not Prolactin, Maintains Low-Level Activation of STAT5a and STAT5b in Female Rat Liver. Endocrinology, 1999, 140, 5126-5135.	2.8	79
62	VEGF Receptor Inhibitors Block the Ability of Metronomically Dosed Cyclophosphamide to Activate Innate Immunityâ€“Induced Tumor Regression. Cancer Research, 2012, 72, 1103-1115.	0.9	79
63	Temporal Relationship Between the Sexually Dimorphic Spontaneous GH Secretory Profiles and Hepatic STAT5 Activity. Endocrinology, 2001, 142, 4599-4606.	2.8	77
64	Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib. Molecular Cancer Therapeutics, 2008, 7, 79-89.	4.1	77
65	Male-Specific Hepatic Bcl6: Growth Hormone-Induced Block of Transcription Elongation in Females and Binding to Target Genes Inversely Coordinated with STAT5. Molecular Endocrinology, 2009, 23, 1914-1926.	3.7	77
66	Role of cellular glutathione and glutathione S-transferase in the expression of alkylating agent cytotoxicity in human breast cancer cells. Biochemical Pharmacology, 1994, 47, 1079-1087.	4.4	76
67	Cytochrome P450 Gene-directed Enzyme Prodrug Therapy (GDEPT) for Cancer. Current Pharmaceutical Design, 2002, 8, 1405-1416.	1.9	76
68	Termination of Growth Hormone Pulse-Induced STAT5b Signaling. Molecular Endocrinology, 1999, 13, 38-56.	3.7	75
69	Use of reverse transcriptionâ€“polymerase chain reaction to evaluatein vivo cytokine gene expression in rats fed ethanol for long periods. Hepatology, 1994, 19, 1483-1487.	7.3	73
70	Exploring the Binding Site Structure of the PPARÎ³ Ligand-Binding Domain by Computational Solvent Mapping. Biochemistry, 2005, 44, 1193-1209.	2.5	71
71	Sex-specific mouse liver gene expression: genome-wide analysis of developmental changes from pre-pubertal period to young adulthood. Biology of Sex Differences, 2012, 3, 9.	4.1	71
72	Changes in Cytochromes P-450, 2E1, 2B1, and 4A, and Phospholipases A and C in the Intragastric Feeding Rat Model for Alcoholic Liver Disease: Relationship to Dietary Fats and Pathologic Liver Injury. Alcoholism: Clinical and Experimental Research, 1994, 18, 902-908.	2.4	70

#	Article	IF	Citations
73	The Structural Basis of Pregnane X Receptor Binding Promiscuity. Biochemistry, 2009, 48, 11572-11581.	2.5	70
74	Sex-Specific Early Growth Hormone Response Genes in Rat Liver. Molecular Endocrinology, 2008, 22, 1962-1974.	3.7	69
75	STAT5b Down-regulates Peroxisome Proliferator-activated Receptor Î± Transcription by Inhibition of Ligand-independent Activation Function Region-1trans-Activation Domain. Journal of Biological Chemistry, 1999, 274, 29874-29882.	3.4	68
76	Synergistic Action of Hepatocyte Nuclear Factors 3 and 6 onCYP2C12 Gene Expression and Suppression by Growth Hormone-activated STAT5b. Journal of Biological Chemistry, 2000, 275, 34173-34182.	3.4	66
77	Down-Regulation of Liver JAK2-STAT5b Signaling by the Female Plasma Pattern of Continuous Growth Hormone Stimulation. Molecular Endocrinology, 1999, 13, 213-227.	3.7	65
78	Intermittent Metronomic Drug Schedule Is Essential for Activating Antitumor Innate Immunity and Tumor Xenograft Regression. Neoplasia, 2014, 16, 84-W27.	5.3	65
79	Role of STAT5a in regulation of sex-specific gene expression in female but not male mouse liver revealed by microarray analysis. Physiological Genomics, 2007, 31, 63-74.	2.3	64
80	Signalling Elements in the Ultradian Rhythm of Circulating Growth Hormone Regulating Expression of Sex-Dependent Forms of Hepatic Cytochrome P450*. Endocrinology, 1989, 125, 2935-2943.	2.8	63
81	Environmental phthalate monoesters activate pregnane X receptor-mediated transcription. Toxicology and Applied Pharmacology, 2004, 199, 266-274.	2.8	63
82	Mini ReviewRole of Hepatocyte Nuclear Factors in Growth Hormone-regulated, Sexually Dimorphic Expression of Liver Cytochromes P450*. Growth Factors, 2004, 22, 79-88.	1.7	63
83	Serine Phosphorylation of GH-Activated Signal Transducer and Activator of Transcription 5a (STAT5a) and STAT5b: Impact on STAT5 Transcriptional Activity. Molecular Endocrinology, 2001, 15, 2157-2171.	3.7	62
84	Role of the Cytokine-induced SH2 Domain-containing Protein CIS in Growth Hormone Receptor Internalization. Journal of Biological Chemistry, 2005, 280, 37471-37480.	3.4	62
85	Use of Replication-Conditional Adenovirus as a Helper System to Enhance Delivery of P450 Prodrug-Activation Genes for Cancer Therapy. Cancer Research, 2004, 64, 292-303.	0.9	61
86	Activation of oxazaphosphorines by cytochrome P450: Application to gene-directed enzyme prodrug therapy for cancer. Toxicology in Vitro, 2006, 20, 176-186.	2.4	61
87	Activation of the anti-cancer drug ifosphamide by rat liver microsomal P450 enzymes. Biochemical Pharmacology, 1993, 45, 1685-1694.	4.4	60
88	Inhibitory Cross-talk between STAT5b and Liver Nuclear Factor HNF3Î². Journal of Biological Chemistry, 2001, 276, 43031-43039.	3.4	59
89	CYTOCHROME P450-BASED CANCER GENE THERAPY: RECENT ADVANCES AND FUTURE PROSPECTS. Drug Metabolism Reviews, 1999, 31, 503-522.	3.6	58
90	Hepatic P450 Expression in Hypothyroid Rats: Differential Responsiveness of Male-Specific P450 Forms 2a (IIIA2), 2c (IIC11), and RLM2 (IIA2) to Thyroid Hormone. Molecular Endocrinology, 1991, 5, 13-20.	3.7	57

#	Article	IF	Citations
91	Changes in Microsomal Phospholipases and Arachidonic Acid in Experimental Alcoholic Liver Injury: Relationship to Cytochrome P-450 2E1 Induction and Conjugated Diene Formation. Alcoholism: Clinical and Experimental Research, 1993, 17, 598-603.	2.4	57
92	Medium dose intermittent cyclophosphamide induces immunogenic cell death and cancer cell autonomous type I interferon production in glioma models. Cancer Letters, 2020, 470, 170-180.	7.2	57
93	[24] Rat hepatic P450IIA and P450IIC subfamily expression using catalytic, immunochemical, and molecular probes. Methods in Enzymology, 1991, 206, 249-267.	1.0	55
94	Impact of dimethyl sulfoxide on expression of nuclear receptors and drug-inducible cytochromes P450 in primary rat hepatocytes. Archives of Biochemistry and Biophysics, 2004, 424, 226-234.	3.0	55
95	Computational prediction of CTCF/cohesin-based intra-TAD loops that insulate chromatin contacts and gene expression in mouse liver. ELife, 2018, 7, .	6.0	55
96	Disruption of STAT5b-Regulated Sexual Dimorphism of the Liver Transcriptome by Diverse Factors Is a Common Event. PLoS ONE, 2016, 11, e0148308.	2.5	55
97	Interaction of Anticancer Drugs with Hepatic Monooxygenase Enzymes. Drug Metabolism Reviews, 1989, 20, 395-439.	3.6	53
98	Down-Regulation of STAT5b Transcriptional Activity by Ligand-Activated Peroxisome Proliferator-Activated Receptor (PPAR) Î± and PPARÎ³. Molecular Pharmacology, 2003, 64, 355-364.	2.3	53
99	Characterization of Three Growth Hormone-Responsive Transcription Factors Preferentially Expressed in Adult Female Liver. Endocrinology, 2007, 148, 3327-3337.	2.8	53
100	Activation of Male Liver Chromatin Accessibility and STAT5-Dependent Gene Transcription by Plasma Growth Hormone Pulses. Endocrinology, 2017, 158, 1386-1405.	2.8	53
101	Aryl hydrocarbon receptor-independent activation of estrogen receptor-dependent transcription by 3-methycholanthrene. Toxicology and Applied Pharmacology, 2006, 213, 87-97.	2.8	52
102	Metronomic cyclophosphamide schedule-dependence of innate immune cell recruitment and tumor regression in an implanted glioma model. Cancer Letters, 2014, 353, 272-280.	7.2	52
103	Long non-coding RNA Gm15441 attenuates hepatic inflammasome activation in response to PPARA agonism and fasting. Nature Communications, 2020, 11, 5847.	12.8	52
104	Cross Talk Between GH-Regulated Transcription Factors HNF6 and CUX2 in Adult Mouse Liver. Molecular Endocrinology, 2015, 29, 1286-1302.	3.7	51
105	Phenotypic differences in expression of cytochrome P-450g but not its mRNA in outbred male Sprague-Dawley rats. Archives of Biochemistry and Biophysics, 1987, 253, 13-25.	3.0	50
106	PC3 prostate tumor-initiating cells with molecular profile FAM65Bhigh/MFI2low/LEF1low increase tumor angiogenesis. Molecular Cancer, 2010, 9, 319.	19.2	50
107	Simultaneous, bidirectional inhibitory crosstalk between PPAR and STAT5b. Toxicology and Applied Pharmacology, 2004, 199, 275-284.	2.8	47
108	Antiangiogenesis Enhances Intratumoral Drug Retention. Cancer Research, 2011, 71, 2675-2685.	0.9	47

#	Article	IF	Citations
109	Feasibility of spatial frequency domain imaging (SFDI) for optically characterizing a preclinical oncology model. Biomedical Optics Express, 2016, 7, 4154.	2.9	47
110	Preparation and characterization of monoclonal antibodies to pregnenolone 16-Î±-carbonitrile inducible rat liver cytochrome P-450. Biochemical Pharmacology, 1986, 35, 2859-2867.	4.4	46
111	[44] P450-catalyzed steroid hydroxylation: Assay and product identification by thin-layer chromatography. Methods in Enzymology, 1991, 206, 462-476.	1.0	46
112	Conditionally Replicating Adenoviruses for Cancer Treatment. Current Cancer Drug Targets, 2007, 7, 285-301.	1.6	45
113	Chemical and Hormonal Effects on STAT5b-Dependent Sexual Dimorphism of the Liver Transcriptome. PLoS ONE, 2016, 11, e0150284.	2.5	45
114	Regulation of Signal Transducer and Activator of Transcription (STAT) 5b Activation by the Temporal Pattern of Growth Hormone Stimulation. Molecular Endocrinology, 1997, 11, 400-414.	3.7	45
115	Sex-Differential Responses of Tumor Promotion-Associated Genes and Dysregulation of Novel Long Noncoding RNAs in Constitutive Androstane Receptor-Activated Mouse Liver. Toxicological Sciences, 2017, 159, 25-41.	3.1	44
116	Posttranslational modification of hepatic cytochrome P-450. Phosphorylation of phenobarbital-inducible P-450 forms PB-4 (IIB1) and PB-5 (IIB2) in isolated rat hepatocytes and in vivo. Biochemistry, 1989, 28, 3145-3152.	2.5	43
117	Environmental and Endogenous Peroxisome Proliferator-Activated Receptor Î³ Agonists Induce Bone Marrow B Cell Growth Arrest and Apoptosis: Interactions between Mono(2-ethylhexyl)phthalate, 9-cis-Retinoic Acid, and 15-Deoxy-Î”12,14-prostaglandin J2. Journal of Immunology, 2004, 173, 3165-3177.	0.8	42
118	ENANTIOSELECTIVE METABOLISM AND CYTOTOXICITY OFR-IFOSFAMIDE ANDS-IFOSFAMIDE BY TUMOR CELL-EXPRESSED CYTOCHROMES P450. Drug Metabolism and Disposition, 2005, 33, 1261-1267.	3.3	42
119	Sex-biased genetic programs in liver metabolism and liver fibrosis are controlled by EZH1 and EZH2. PLoS Genetics, 2020, 16, e1008796.	3.5	42
120	Interaction of a Novel Sex-dependent, Growth Hormone-regulated Liver Nuclear Factor with CYP2C12 Promoter. Journal of Biological Chemistry, 1996, 271, 29978-29987.	3.4	41
121	Identification of glutathione S-transferase as a determinant of 4-hydroperoxycyclophosphamide resistance in human breast cancer cells. Biochemical Pharmacology, 1995, 49, 1691-1701.	4.4	40
122	Dominant Effect of Antiangiogenesis in Combination Therapy Involving Cyclophosphamide and Axitinib. Clinical Cancer Research, 2009, 15, 578-588.	7.0	40
123	Enhanced antitumor activity of P450 prodrug-based gene therapy using the low Km cyclophosphamide 4-hydroxylase P450 2B11. Molecular Cancer Therapeutics, 2006, 5, 541-555.	4.1	39
124	Growth Hormone Pulse-Activated STAT5 Signalling: A Unique Regulatory Mechanism Governing Sexual Dimorphism of Liver Gene Expression. Novartis Foundation Symposium, 2008, 227, 61-81.	1.1	39
125	Hepatic Long Intergenic Noncoding RNAs: High Promoter Conservation and Dynamic, Sex-Dependent Transcriptional Regulation by Growth Hormone. Molecular and Cellular Biology, 2016, 36, 50-69.	2.3	39
126	Dynamic in Vivo Binding of STAT5 to Growth Hormone-Regulated Genes in Intact Rat Liver. Sex-Specific Binding at Low- But Not High-Affinity STAT5 Sites. Molecular Endocrinology, 2009, 23, 1242-1254.	3.7	38

#	Article	IF	Citations
127	STAT5b Is Required for GH-Induced Liver Igf-I Gene Expression. Endocrinology, 2001, 142, 3836-3841.	2.8	38
128	Isolation and characterization of cDNA clones for cytochromes P-450 immunochemically related to rat hepatic P-450 form PB-1. Biochemistry, 1986, 25, 7975-7983.	2.5	37
129	Impact of liver P450 reductase suppression on cyclophosphamide activation, pharmacokinetics and antitumoral activity in a cytochrome P450-based cancer gene therapy model. Cancer Gene Therapy, 2000, 7, 1034-1042.	4.6	37
130	Toxicity of ethylene glycol monomethyl ether: impact on testicular gene expression. Journal of Developmental and Physical Disabilities, 2008, 31, 269-274.	3.6	37
131	Differential apoprotein loss of rat liver cytochromes P450 after their inactivation by 3,5-dicarbethoxy-2,6-dimethyl-4-ethyl-1,4-dihydropyridine: A case for distinct proteolytic mechanisms?. Archives of Biochemistry and Biophysics, 1992, 294, 493-503.	3.0	36
132	Changes in Mouse Uterine Transcriptome in Estrus and Proestrus1. Biology of Reproduction, 2013, 89, 13.	2.7	36
133	MAnorm2 for quantitatively comparing groups of ChIP-seq samples. Genome Research, 2021, 31, 131-145.	5.5	36
134	Hormonal Regulation of Levels of the Messenger RNA Encoding Hepatic P450 2c (IIC11), a Constitutive Male-Specific Form of Cytochrome P450. Molecular Endocrinology, 1990, 4, 295-303.	3.7	35
135	Computational Solvent Mapping Reveals the Importance of Local Conformational Changes for Broad Substrate Specificity in Mammalian Cytochromes P450â€. Biochemistry, 2006, 45, 9393-9407.	2.5	35
136	Phosphorylation of carcinogen metabolizing enzymes: regulation of the phosphorylation status of the major phenobarbital inducible cytochromes P-450 in hepatocytes. Carcinogenesis, 1989, 10, 225-228.	2.8	34
137	Multi-modal characterization of vasculature and nanoparticle accumulation in five tumor xenograft models. Journal of Controlled Release, 2018, 279, 292-305.	9.9	34
138	Sex-Biased lncRNAs Inversely Correlate With Sex-Opposite Gene Coexpression Networks in Diversity Outbred Mouse Liver. Endocrinology, 2019, 160, 989-1007.	2.8	34
139	Rat hepatic cholesterol 7Î±-hydroxylase: Biochemical properties and comparison to constitutive and xenobiotic-inducible cytochrome P-450 enzymes. Archives of Biochemistry and Biophysics, 1986, 247, 335-345.	3.0	33
140	Antitumor alkylating agents: in vitro cross-resistance and collateral sensitivity studies. Cancer Chemotherapy and Pharmacology, 1993, 33, 113-122.	2.3	33
141	Identification of novel enzymeâ€“prodrug combinations for use in cytochrome P450-based gene therapy for cancer. Archives of Biochemistry and Biophysics, 2003, 409, 197-206.	3.0	33
142	Plasma Growth Hormone Pulse Activation of Hepatic JAK-STAT5 Signaling: Developmental Regulation and Role in Male-Specific Liver Gene Expression. Endocrinology, 2000, 141, 3245-3255.	2.8	33
143	Monoclonal antibodies to rat liver cytochrome P-450 2c/RLM5 that regiospecifically inhibit steroid metabolism. Biochemical Pharmacology, 1989, 38, 3067-3074.	4.4	32
144	Metronomic cyclophosphamide activation of anti-tumor immunity: tumor model, mouse host, and drug schedule dependence of gene responses and their upstream regulators. BMC Cancer, 2016, 16, 623.	2.6	32

#	Article	IF	Citations
145	Depletion of Serum Growth Hormone in Adult Female Rats by Neonatal Monosodium Glutamate Treatment without Loss of Female-Specific Hepatic Enzymes P450 2d (IIC12) and Steroid 5Î±-Reductase*. Endocrinology, 1990, 126, 712-720.	2.8	31
146	Sexual dimorphism of hepatic gene expression: novel biological role of KRAB zinc finger repressors revealed. Genes and Development, 2003, 17, 2607-2613.	5.9	31
147	Sexual Dimorphism of Rat Liver Nuclear Proteins. Molecular and Cellular Proteomics, 2004, 3, 1170-1180.	3.8	31
148	CpG-1826 immunotherapy potentiates chemotherapeutic and anti-tumor immune responses to metronomic cyclophosphamide in a preclinical glioma model. Cancer Letters, 2016, 373, 88-96.	7.2	31
149	Re-engineering cytochrome P450 2B11dH for enhanced metabolism of several substrates including the anti-cancer prodrugs cyclophosphamide and ifosfamide. Archives of Biochemistry and Biophysics, 2007, 458, 167-174.	3.0	30
150	Functional Roles of Sex-Biased, Growth Hormoneâ€“Regulated MicroRNAs miR-1948 and miR-802 in Young Adult Mouse Liver. Endocrinology, 2018, 159, 1377-1392.	2.8	30
151	Computational Screening of Phthalate Monoesters for Binding to PPARÎ³. Chemical Research in Toxicology, 2006, 19, 999-1009.	3.3	29
152	Differential effects of neonatally administered glutamate on the ultradian pattern of circulating growth hormone regulating expression of sex-dependent forms of cytochrome P450. Biochemical Pharmacology, 1991, 41, 1299-1309.	4.4	28
153	Modulation of cyclophosphamide-based cytochrome P 450 gene therapy using liver P450 inhibitors. Cancer Gene Therapy, 2001, 8, 450-458.	4.6	27
154	Down-Regulation of Liver JAK2-STAT5b Signaling by the Female Plasma Pattern of Continuous Growth Hormone Stimulation. Molecular Endocrinology, 1999, 13, 213-227.	3.7	27
155	Signalling cross-talk between hepatocyte nuclear factor 4Î± and growth-hormone-activated STAT5b. Biochemical Journal, 2006, 397, 159-168.	3.7	26
156	Thrombospondin-1 and pigment epithelium-derived factor enhance responsiveness of KM12 colon tumor to metronomic cyclophosphamide but have disparate effects on tumor metastasis. Cancer Letters, 2013, 330, 241-249.	7.2	26
157	Microheterogeneity of a male-specific rat hepatic cytochrome P-450: Existence of three allozymic forms. Archives of Biochemistry and Biophysics, 1985, 243, 174-183.	3.0	25
158	Role of Hepatocyte Nuclear Factors in Transcriptional Regulation of Male-specific CYP2A2. Journal of Biological Chemistry, 2005, 280, 3259-3268.	3.4	25
159	Mouse lung CYP1A1 catalyzes the metabolic activation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). Carcinogenesis, 2006, 28, 732-737.	2.8	25
160	A Mouse Model with Liver-Specific Deletion and Global Suppression of the NADPH-Cytochrome P450 Reductase Gene: Characterization and Utility for in Vivo Studies of Cyclophosphamide Disposition. Journal of Pharmacology and Experimental Therapeutics, 2007, 321, 9-17.	2.5	25
161	Human Telomerase Reverse Transcriptase Promoter-Driven Oncolytic Adenovirus with E1B-19â€‰kDa and E1B-55â€‰kDa Gene Deletions. Human Gene Therapy, 2008, 19, 1383-1399.	2.7	25
162	Human liver folylpolyglutamate synthetase: Biochemical characterization and interactions with folates and folate antagonists. Archives of Biochemistry and Biophysics, 1987, 256, 585-596.	3.0	24

#	Article	IF	Citations
163	Elevated Basal Expression of Liver Peroxisomal Î²-Oxidation Enzymes and CYP4A Microsomal Fatty Acid Ï‰-Hydroxylase in STAT5bâ^'/â^' Mice: Cross-Talk in Vivo between Peroxisome Proliferator-Activated Receptor and Signal Transducer and Activator of Transcription Signaling Pathways. Toxicology and Applied Pharmacology, 2002, 182, 1-10.	2.8	24
164	Collaboration between hepatic and intratumoral prodrug activation in a P450 prodrug-activation gene therapy model for cancer treatment. Molecular Cancer Therapeutics, 2007, 6, 2879-2890.	4.1	24
165	SECONDARY STRUCTURE RELATIONS BETWEEN BETAâ€ŁACTAMASES AND PENICILLINâ€SENSITIVE Dâ€"ALANINEâ€"CARBOXYPEPTIDASES. International Journal of Peptide and Protein Research, 1981, 17, 211-218.	0.1	24
166	Anti-tumor innate immunity activated by intermittent metronomic cyclophosphamide treatment of 9L brain tumor xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2. Molecular Cancer, 2014, 13, 158.	19.2	24
167	Termination of Growth Hormone Pulse-Induced STAT5b Signaling. Molecular Endocrinology, 1999, 13, 38-56.	3.7	24
168	Antitumor Activity of Methoxymorpholinyl Doxorubicin: Potentiation by Cytochrome P450 3A Metabolism. Molecular Pharmacology, 2005, 67, 212-219.	2.3	23
169	Interactions of methoxyacetic acid with androgen receptor. Toxicology and Applied Pharmacology, 2009, 238, 101-110.	2.8	23
170	Delicate Balances in Cancer Chemotherapy: Modeling Immune Recruitment and Emergence of Systemic Drug Resistance. Frontiers in Immunology, 2020, 11, 1376.	4.8	23
171	Enhanced bystander cytotoxicity of P450 gene-directed enzyme prodrug therapy by expression of the antiapoptotic factor p35. Cancer Research, 2002, 62, 6928-37.	0.9	23
172	Thyroid Regulation of NADPH:Cytochrome P450 Oxidoreductase: Identification of a Thyroid-Responsive Element in the 5â€²-Flank of the Oxidoreductase Gene. Molecular Pharmacology, 1997, 52, 46-53.	2.3	22
173	Regulation of Human CYP2C18 and CYP2C19 in Transgenic Mice: Influence of Castration, Testosterone, and Growth Hormone. Drug Metabolism and Disposition, 2009, 37, 1505-1512.	3.3	22
174	Potentiation of methoxymorpholinyl doxorubicin antitumor activity by P450 3A4 gene transfer. Cancer Gene Therapy, 2009, 16, 393-404.	4.6	22
175	DNase I Digestion of Isolated Nulcei for Genome-Wide Mapping of DNase Hypersensitivity Sites in Chromatin. Methods in Molecular Biology, 2013, 977, 21-33.	0.9	22
176	Growth Hormone, but Not Prolactin, Maintains Low-Level Activation of STAT5a and STAT5b in Female Rat Liver. Endocrinology, 1999, 140, 5126-5135.	2.8	22
177	Interplay Between GH-regulated, Sex-biased Liver Transcriptome and Hepatic Zonation Revealed by Single-Nucleus RNA Sequencing. Endocrinology, 2022, 163, .	2.8	22
178	Interaction of penicillin with its receptors in bacterial membranes. Trends in Biochemical Sciences, 1980, 5, 97-101.	7.5	21
179	Loss of growth hormoneâ€"mediated signal transducer and activator of transcription 5 (STAT5) signaling in mice results in insulin sensitivity with obesity. FASEB Journal, 2019, 33, 6412-6430.	0.5	21
180	STAT5 Regulation of Sex-Dependent Hepatic CpG Methylation at Distal Regulatory Elements Mapping to Sex-Biased Genes. Molecular and Cellular Biology, 2021, 41, .	2.3	21

#	Article	IF	Citations
181	Hormonal Regulation of Liver Cytochrome P450 Enzymes. , 1995, , 391-417.		21
182	Post-Transcriptional Regulation of Hepatic NADPH-Cytochrome P450 Reductase by Thyroid Hormone: Independent Effects on Poly(A) Tail Length and mRNA Stability. Molecular Pharmacology, 2002, 61, 1089-1096.	2.3	20
183	Use of 7-Ethoxycoumarin to Monitor Multiple Enzymes in the Human CYP1, CYP2, and CYP3 Families. , 2006, 320, 153-156.		20
184	Enhancement of intratumoral cyclophosphamide pharmacokinetics and antitumor activity in a P450 2B11-based cancer gene therapy model. Cancer Gene Therapy, 2007, 14, 935-944.	4.6	20
185	Regulation of drug metabolism and toxicity by multiple factors of genetics, epigenetics, lncRNAs, gut microbiota, and diseases: a meeting report of the 21st International Symposium on Microsomes and Drug Oxidations (MDO). Acta Pharmaceutica Sinica B, 2017, 7, 241-248.	12.0	20
186	Hormonal perturbations in patients with testicular cancer treated with cisplatin. Cancer, 1992, 69, 2306-2310.	4.1	19
187	Early programing of uterine tissue by bisphenol A: Critical evaluation of evidence from animal exposure studies. Reproductive Toxicology, 2015, 57, 59-72.	2.9	19
188	Transcriptional profiling provides insights into metronomic cyclophosphamide-activated, innate immune-dependent regression of brain tumor xenografts. BMC Cancer, 2015, 15, 375.	2.6	18
189	Impact of CAR Agonist Ligand TCPOBOP on Mouse Liver Chromatin Accessibility. Toxicological Sciences, 2018, 164, 115-128.	3.1	18
190	Impact of 3D genome organization, guided by cohesin and CTCF looping, on sex-biased chromatin interactions and gene expression in mouse liver. Epigenetics and Chromatin, 2020, 13, 30.	3.9	18
191	Î²-Lactam Antibiotics: Biochemical Modes of Action. , 1982, , 209-285.		17
192	Antibodies targeted against hypervariable and constant regions of cytochromes P450IIB1 and P450IIB2. Archives of Biochemistry and Biophysics, 1989, 270, 23-32.	3.0	17
193	Sustained P450 expression and prodrug activation in bolus cyclophosphamide-treated cultured tumor cells. Impact of prodrug schedule on P450 gene-directed enzyme prodrug therapy. Cancer Gene Therapy, 2003, 10, 571-582.	4.6	17
194	Enzymatic Analysis of cDNA-Expressed Human CYP1A1, CYP1A2, and CYP1B1 With 7-Ethoxyresorufin as Substrate. , 2006, 320, 85-90.		17
195	Impact of Tumor Vascularity on Responsiveness to Antiangiogenesis in a Prostate Cancer Stem Cell-Derived Tumor Model. Molecular Cancer Therapeutics, 2013, 12, 787-798.	4.1	17
196	Metabolism of methotrexate and Î³-tert-butyl methotrexate by human leukemic cells in culture and by hepatic aldehyde oxidase in vitro. Biochemical Pharmacology, 1987, 36, 2209-2214.	4.4	16
197	High-Performance Liquid Chromatographicâ€“Fluorescent Method to Determine Chloroacetaldehyde, a Neurotoxic Metabolite of the Anticancer Drug Ifosfamide, in Plasma and in Liver Microsomal Incubations. Analytical Biochemistry, 1999, 273, 117-125.	2.4	16
198	Cytochrome P-450 cholesterol 7Î±-hydroxylase: Inhibition of enzyme deactivation by structurally diverse calmodulin antagonists and phosphatase inhibitors. Archives of Biochemistry and Biophysics, 1987, 256, 543-559.	3.0	15

#	Article	IF	Citations
199	Rat Liver Cytochrome P450 2B3: Structure of theCYP2B3Gene and Immunological Identification of a Constitutive P450 2B3-Like Protein in Rat Liver. DNA and Cell Biology, 1994, 13, 781-792.	1.9	15
200	Spectrofluorometric Analysis of CYP2A6-Catalyzed Coumarin 7-Hydroxylation. , 1998, 107, 111-116.		15
201	Impact of methoxyacetic acid on mouse Leydig cell gene expression. Reproductive Biology and Endocrinology, 2010, 8, 65.	3.3	14
202	Hormonal Regulation of Liver Cytochrome P450 Enzymes. , 2015, , 813-850.		14
203	Transcriptional Induction of Hepatic NADPH: Cytochrome P450 Oxidoreductase by Thyroid Hormone. Molecular Pharmacology, 2001, 59, 987-995.	2.3	14
204	Hormonal Regulation of Liver Cytochrome P450 Enzymes. , 2005, , 347-376.		13
205	Wavelength-dependent backscattering measurements for quantitative monitoring of apoptosis, Part 2: early spectral changes during apoptosis are linked to apoptotic volume decrease. Journal of Biomedical Optics, 2011, 16, 117002.	2.6	13
206	Widespread Dysregulation of Long Noncoding Genes Associated With Fatty Acid Metabolism, Cell Division, and Immune Response Gene Networks in Xenobiotic-exposed Rat Liver. Toxicological Sciences, 2020, 174, 291-310.	3.1	13
207	Global analysis of expression, maturation and subcellular localization of mouse liver transcriptome identifies novel sex-biased and TCPOBOP-responsive long non-coding RNAs. BMC Genomics, 2021, 22, 212.	2.8	13
208	Constitutively Active STAT5b Feminizes Mouse Liver Gene Expression. Endocrinology, 2022, 163, .	2.8	13
209	Suppression of male-specific cytochrome P450 2c and its mRNA by 3,4,5,3â€²,4â€²,5â€²-hexachlorobiphenyl in rat liver is not causally related to changes in serum testosterone. Archives of Biochemistry and Biophysics, 1989, 271, 508-514.	3.0	12
210	Influence of lipophilicity and carboxyl group content on the rate of hydroxylation of methotrexate derivatives by aldehyde oxidase. Biochemical Pharmacology, 1990, 40, 851-857.	4.4	12
211	Adenoviral delivery of pan-caspase inhibitor p35 enhances bystander killing by P450 gene-directed enzyme prodrug therapy using cyclophosphamide+. BMC Cancer, 2010, 10, 487.	2.6	12
212	Complex modulation of androgen responsive gene expression by methoxyacetic acid. Reproductive Biology and Endocrinology, 2011, 9, 42.	3.3	12
213	Genetic factors contributing to extensive variability of sex-specific hepatic gene expression in Diversity Outbred mice. PLoS ONE, 2020, 15, e0242665.	2.5	12
214	Amino acid sequence homologies betweenEscherichia colipenicillin-binding protein 5 and class a Î²-lactamases. FEBS Letters, 1982, 139, 159-163.	2.8	11
215	[29] P450 Phosphorylation in isolated hepatocytes and in Vivo. Methods in Enzymology, 1991, 206, 305-315.	1.0	11
216	Interactions of Endocrine-active environmental chemicals with the nuclear receptor PXR. Toxicological and Environmental Chemistry, 2005, 87, 299-311.	1.2	11

#	Article	IF	Citations
217	The induction of atherogenic dyslipidaemia in poloxamer 407-treated mice is not mediated through PPARÎ±. Journal of Pharmacy and Pharmacology, 2010, 60, 753-759.	2.4	11
218	Circulating free fatty acids are increased independently of PPARÎ³ activity after administration of poloxamerÂ407 to mice. Canadian Journal of Physiology and Pharmacology, 2008, 86, 643-649.	1.4	10
219	Wavelength-dependent backscattering measurements for quantitative monitoring of apoptosis, Part 1: early and late spectral changes are indicative of the presence of apoptosis in cell cultures. Journal of Biomedical Optics, 2011, 16, 117001.	2.6	10
220	Impact of Tumor Blood Flow Modulation on Tumor Sensitivity to the Bioreductive Drug Banoxantrone. Journal of Pharmacology and Experimental Therapeutics, 2013, 344, 368-377.	2.5	10
221	Adenoviral Vectors for Prodrug Activation-based Gene Therapy for Cancer. Anti-Cancer Agents in Medicinal Chemistry, 2014, 14, 115-126.	1.7	10
222	Next generation metronomic chemotherapyâ€"report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6â€"8 May 2016, Mumbai. Ecancermedicalscience, 2016, 10, 689.	1.1	10
223	Widespread Epigenetic Changes to the Enhancer Landscape of Mouse Liver Induced by a Specific Xenobiotic Agonist Ligand of the Nuclear Receptor CAR. Toxicological Sciences, 2019, 171, 315-338.	3.1	10
224	Growth Hormone Action: Signaling via a JAK/STAT-Coupled Receptor. , 0, , 55-83.		10
225	Catalytic Assays for Human Cytochrome P450: An Introduction. , 2006, 320, 73-84.		9
226	Cytochrome-P450 2B1 gene silencing attenuates puromycin aminonucleoside-induced cytotoxicity in glomerular epithelial cells. Kidney International, 2010, 78, 182-190.	5.2	9
227	Evaluation of thyroid hormone effects on liver P450 reductase translation. Archives of Biochemistry and Biophysics, 2003, 409, 172-179.	3.0	8
228	Pregnane X Receptorâ€Mediated Transcription. Methods in Enzymology, 2005, 400, 588-598.	1.0	8
229	Cytochrome P450 2B1 Mediates Complement-dependent Sublytic Injury in a Model of Membranous Nephropathy. Journal of Biological Chemistry, 2010, 285, 40901-40910.	3.4	8
230	Isolation of Nuclei for Use in Genome-Wide DNase Hypersensitivity Assays to Probe Chromatin Structure. Methods in Molecular Biology, 2013, 977, 13-19.	0.9	8
231	Optical scattering as an early marker of apoptosis during chemotherapy and antiangiogenic therapy in murine models of prostate and breast cancer. Neoplasia, 2021, 23, 294-303.	5.3	8
232	Monoclonal antibodies to rat liver microsomal cytochrome b5. Biochemical Pharmacology, 1992, 43, 2201-2208.	4.4	6
233	Growth Hormone (GH). , 2003, , 208-216.		6
234	Determination of CYP2B6 Component of 7-Ethoxy-4-Trifluoromethylcoumarin O-Deethylation Activity in Human Liver Microsomes. , 2006, 320, 97-102.		6

#	Article	IF	Citations
235	Determination of CYP2C9-Catalyzed Diclofenac 4'-Hydroxylation by High-Performance Liquid Chromatography. , 2006, 320, 109-114.		5
236	Harnessing natural variation to identify cis regulators of sex-biased gene expression in a multi-strain mouse liver model. PLoS Genetics, 2021, 17, e1009588.	3.5	5
237	Cytochrome P450-Based Gene Therapies for Cancer. , 2004, 90, 203-222.		4
238	Spectrofluorometric Analysis of CYP2A6-Catalyzed Coumarin 7-Hydroxylation. , 2006, 320, 91-96.		4
239	H460 non-small cell lung cancer stem-like holoclones yield tumors with increased vascularity. Cancer Letters, 2014, 346, 63-73.	7.2	4
240	Evidence for an oncogenic modifier role for mutant histone acetyltransferases in diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2016, 57, 2661-2671.	1.3	4
241	Impact of Neonatal Activation of Nuclear Receptor CAR (<scp>Nr</scp>1<scp>i</scp>3) on Cyp2 Gene Expression in Adult Mouse Liver. Toxicological Sciences, 2022, 187, 298-310.	3.1	4
242	Type-I Interferon Signaling Is Essential for Robust Metronomic Chemo-Immunogenic Tumor Regression in Murine Breast Cancer. Cancer Research Communications, 2022, 2, 246-257.	1.7	4
243	Steroid Hormones and other Physiologic Regulators of Liver Cytochromes P450: Metabolic Reactions and Regulatory Pathways. Advances in Molecular and Cell Biology, 1996, , 341-374.	0.1	3
244	High-Performance Liquid Chromatography Analysis of CYP2C8-Catalyzed Paclitaxel 6Î±-Hydroxylation. , 2006, 320, 103-108.		3
245	Spatial frequency domain imaging for monitoring immune-mediated chemotherapy treatment response and resistance in a murine breast cancer model. Scientific Reports, 2022, 12, 5864.	3.3	3
246	Thin-Layer Chromatography Analysis of Human CYP3A-Catalyzed Testosterone 6Î²-Hydroxylation. , 2006, 320, 133-142.		2
247	Construction of P450-Expressing Tumor Cell Lines Using Retroviruses. , 2000, 35, 85-94.		1
248	An Isocratic High-Performance Liquid Chromatography Assay for CYP7A1-Catalyzed Cholesterol 7Î±-Hydroxylation. , 2006, 320, 149-152.		1
249	CYP2C19-Mediated (S)-Mephenytoin 4'-Hydroxylation Assayed by High-Performance Liquid Chromatography With Radiometric Detection. , 2006, 320, 115-120.		1
250	Thin-layer chromatography analysis of human CYP3A-catalyzed testosterone 6beta-hydroxylation. Methods in Molecular Biology, 2006, 320, 133-41.	0.9	1
251	An isocratic high-performance liquid chromatography assay for CYP7A1-catalyzed cholesterol 7alpha-hydroxylation. Methods in Molecular Biology, 2006, 320, 149-52.	0.9	1
252	Thin-Layer Chromatographic Analysis of Human CYP3A-Catalyzed Testosterone 6P-Hydroxylation. , 1998, 107, 153-162.		0

#	Article	IF	Citations
253	Selection of Cytochrome P450Genes for Use in Prodrug Activation-Based Cancer Gene Therapy. , 2000, 35, 77-83.		0
254	In Vitro Methods for Evaluation of P450-Based Anticancer Gene Therapy. , 2000, 35, 95-105.		0
255	Role of STATs in the Biological Functions of Growth Hormone. , 2003, , 525-544.		0
256	hTERT-promoter driven oncolytic adenovirus with E1B-19 kDa and E1B-55 kDa gene deletions. Human Gene Therapy, 2008, .	2.7	0
257	Activators of CAR and PXR Rapidly Alter Chromatin Accessibility in Mouse Liver. FASEB Journal, 2013, 27, lb628.	0.5	0
258	Sexual Dimorphism of Liver Cytochrome P-450 Gene Expression: GH Pulse-Activated STAT Signaling Mechanisms. , 1999, , 327-336.		0
259	Optical scattering as an early marker of apoptosis during chemotherapy and antiangiogenic therapy in murine models of prostate and breast cancer. , 2021, , .		0
260	Sex-biased genetic programs in liver metabolism and liver fibrosis are controlled by EZH1 and EZH2. , 2020, 16, e1008796.		0
261	Sex-biased genetic programs in liver metabolism and liver fibrosis are controlled by EZH1 and EZH2. , 2020, 16, e1008796.		0
262	Sex-biased genetic programs in liver metabolism and liver fibrosis are controlled by EZH1 and EZH2. , 2020, 16, e1008796.		0
263	Sex-biased genetic programs in liver metabolism and liver fibrosis are controlled by EZH1 and EZH2. , 2020, 16, e1008796.		0